May 27, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

NRG Oncology Summer Meeting Registration is OPEN

More information can be found on our

Summer Meeting

webpage. 

NRG SUMMER MEETING

NRG Oncology Summer Meeting Registration is Now Open!

Join us in Washington DC for the NRG2025 Summer Meeting. The meeting will be held in-person at the Marriott Marquis, July 24-26, 2025, with select virtual sessions being held July 16-25, 2025. Register soon to avoid the late registration fee!

More information | Agenda | Register

Real ID Reminder - Travel Requirements

As of May 7, 2025, a REAL ID or another acceptable form of identification, like a passport, is required to board domestic flights. Please visit the DHS website for more information on this travel requirement.

NRG Summer 2025 Symposium - Antibody Drug Conjugates: Selection, Sequencing and Future Strategies in Solid Tumors

Join us on in Washington, DC on Thursday, July 24, 2025 from 8am-12pm ET. The session will also be available virtually. This symposium offers a valuable opportunity to explore the expanding role of ADCs in the treatment of ovarian, cervical, endometrial, breast, lung, genitourinary and gastrointestinal cancers, highlighting their impact on clinical practice and patient outcomes. Program Chair - Kathleen Moore, MD and Co-Chair - Paolo Tarantino, MD

More information | Register

NRG Advanced Practice Provider (APP) Symposium

Calling all APPs! We are pleased to announce our NRG Oncology Advanced Practice Providers (APP) Symposium to be held during the NRG2025 Summer Meeting in Washington, DC on Friday, July 25, 2025, 8:15-9:45am ET. The session will also be available virtually. The goals for the session will be to identify the different roles that APPs can serve in NCI-sponsored research and elevate their involvement in clinical research at practice sites. The session chairs are Deb Bruner, Kathleen Castro, Christa Braun-Inglis, and Melyssa Foust.

More information | Register

TERMINATIONS

GYNECOLOGIC

GOG-0258: Terminated January 26, 2025; version date: April 4, 2014 (posted on CTSU)

GOG-0278: Terminated March 7, 2025; version date: August 12, 2021 (posted on NRG Oncology)

GOG-0286B: Terminated April 1, 2025; version date: June 21, 2017 (posted on NRG Oncology)

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANKS

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BREAST

NRG-BR008/HERO: Reminder that this trial is open and actively enrolling patients. Helpful materials pertaining to BR008 can be found on the NRG Oncology website under Clinical Trials/NRG-BR008/Documents & Materials or on the CTSU website.

4. CANCER PREVENTION & CONTROL

NRG-CC008: The study was redesigned to remove the age blocking that required closure of an age/arm cohort. Each age/arm cohort will now remain open to accrual until meeting its target accrual. Thus, the BSO 42-50 years old cohort (previously closed) re-opened to accrual on May 19, 2025 with the release of amendment 7.

5. GENITOURINARY

NRG-GU012: Spanish Consent Form and Translation approval, dated April 22, 2025 (posted on CTSU)

6. GYNECOLOGIC

NRG-GY025: Reminder! Enrollment for this study is still open to all NCTN sites.

NRG-GY026: Now accruing patients of all stages and all histologic subtypes of endometrial cancer.

NRG-GY031: Please note, there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

7. HEAD & NECK

NRG-HN014: Expedited Study Activation Funding Update

We are excited to announce that the first 25 site networks participating in NRG-HN014 have successfully completed all required regulatory and training activities to qualify for non-federal expedited study activation funding. This achievement highlights the commitment and hard work of our participating sites. We extend our sincere appreciation for your dedication and continued efforts to advance this important trial. At this time, please note that all available expedited activation funds have been allocated, and no additional funding is available for distribution under this initiative. Thank you for your ongoing support and collaboration on NRG-HN014.

NRG-HN008 - Reminder: please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important. 

8. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC003, NRG-CC005, NRG-CC011, NRG-CC013, NRG-CC014, NRG-HN001, NRG-HN002, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for June 11, 2025.

2. REGISTER TODAY: The NRG-GU012 (SAMURAI) Webinar

The NRG-GU012 “SAMURAI” Study Principal Investigators will be hosting a webinar to discuss the trial and accept any questions regarding the study from sites. This webinar will be held on Friday, June 13 from 12-1pm ET / 9-10am PT. NRG-GU012 is a Phase II study of stereotactic ablative radiation therapy (SABR) for patients with unresected renal cell carcinoma receiving immunotherapy.

Register here.

4. Regeneron Reception at ASCO featuring NRG-HN014

Regeneron is hosting a special reception at ASCO on Sunday, June 1, 6-8pm CT, to showcase their Skin Cancer Pipeline, featuring the exciting NRG-HN014 clinical trial. Investigators interested in attending are encouraged to RSVP via the invitation posted here.

5. Healthcare Access Committee (HCA) Symposium Recording Now Available

The recording of the NRG Healthcare Access Committee Annual Symposium, Conquering the Geospatial Divide Challenging Rural Research & Cancer Care Delivery: Real world discussions with rural providers, trialists, and patient caregivers, (April 30, 2025) is now posted under the NRG Healthcare Access Committee page on the NRG Oncology website (login required).

6. RFA for the NRG Patient Advocate Committee – PCOR and Ovarian Cancer Representatives

Applications DUE June 9, 2025 - Read more and how to apply

7. REMINDER! GYN Cancer Committee is Requesting Proposals in Advance of the NRG Winter Meeting

Submission Deadline: June 20, 2025

Submit completed proposals to GYNconcepts@nrgoncology.org. See details here.

8. NRG Member Information Form

We are excited to introduce the NRG Member Information Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

NRG Oncology is pleased to report the scientific articles that appeared during the previous week, as well as abstracts accepted for presentation at the 2025 American Society for Radiation Oncology and the Australia New Zealand Head Neck Cancer Society meetings.

This publications report includes links, when available, to the article, PubMed abstract, or association abstract.

ACCEPTED ABSTRACTS

Chen R, Pugh SL, Ganz P, Padula GD, Koontz B, Cannick L, Vetter PJ, Thomas O, Yoon HA, Abdalla I, Mackley H, Chapman CH, Cheney MD, Kilburn JM, McTyre E, Gupta-Burt S, Paulus R, Cooley ME. Impact of intensified survivorship care planning on cardiovascular care in prostate cancer survivors: primary results of NRG-CC007CD. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 158; 9/28/2025 Oral Presentation.

Chinn SB, Ma X, Tierney M, Moatadelro A, Rosten E, Rosenthal D, Caudell JJ, Dunlap N, Jones CU, Woody NM, Galloway TJ, Nguyen-Tan PF, Raben A, Shenouda G, Blakaj DM, Firat S, Machtay M, Le Q, Schipper M, Yom SS. Development and Validation of a Digital Pathology-Based, Multimodal Artificial Intelligence (MMAI) Biomarker in Patients with Head and Neck Cancer. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 177; 9/29/2025 Oral Presentation.

Ellis RJ, Pugh SL, Yu JB, Feng FY, Konski AA, Grubb III RL, Wallace RE, Gladstone DJ, Menard C, Frazier AJ, Pennington JD, Michalski JM, Spratt DE, Martinez A, Morgan SC, Mihai A, Paulus R, Sandler HM. Primary results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 1; 9/28/2025 Oral Presentation; 9/29/2025, Plenary Session.

Geng H, White JR, Harris EE, Bazan JG, Cecchini RS, Chen G, Betler JA, Seaward SA, Sharp HJ, Properq M, Sarma K, Le-Lindqwister N, Tinger A, Biswas T, Lyons J, Anderson BM, Sikov WM, Mamounas EP, Xiao Y. Feasibility Study of AI-Assisted Radiation Therapy Contour QA for Breast Cancer Multi-Center Clinical Trial. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 2938; 9/29/2025 Poster Presentation.

Goetz A, Smith S, Dressler EV, Page BR, Wefel JS, Rapp SR, Ip EH, Gilbert MR, Pugh SL, Sumrall AL, Weaver KE, Lesser GJ, Chan MD, Cramer CK. WF-1801: Cognitive Outcomes of a Single Arm Pilot Study of Ramipril for Prevention of Radiation-Induced Cognitive Decline in Glioblastoma Patients Receiving Chemoradiotherapy. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 285; 9/30/2025 Oral Presentation.

Johnson BA, Hu C, Hoppe BS, Simone CB II, Liao Z, Kotecha RR, Samson P, Stokes WA, Nguyen Q, Narayan S, Raben A, Iheagwara U, Garces YI, Wu AJ, Gerber D, Vicetic GM, Lyness JA, Bradley JD. Sociodemographic Factors Associated with Proton Therapy Accessibility in NRG Oncology Trials of Locally Advanced NSCLC. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 2391; 9/28/2025 Poster Presentation.

Khan AJ, Gu X, Tang G, Yu G, Cecchini RS, Julian TB, Mamounas EP, White JR, Vicini FA. Utilization of a Lumpectomy Bed Boost after Whole Breast Radiotherapy Does Not Improve Ipsilateral Breast Tumor Recurrence Risk in Patients with Ductal Carcinoma In-Situ Treated on Three NSABP Trials. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 2954; 9/30/2025 Oral Presentation.

Kachnic LA, Winter KA, Abrams RA, Regine WF, Goodman KA, Lowy AM, Seaward SA, Wu AJ, Ramalingam A, Hatoum H, DiPetrillo TA, Geva R, Haddock MG, Wu JJ, Moughan J, Movsas B, Hong TS. Is patient-reported baseline fatigue associated with overall survival among resected head of the pancreas adenocarcinoma patients on NRG Oncology/RTOG 0848? American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 162; 9/28/2025 Oral Presentation.

Kim S, Enserro DM, Lankes HA, DaSilva D, Pham H, Moore K, Ghamande S, Aghajanian C, Schilder RJ, Matsuo K, Birrer MJ, Sharabi A, Mayadev J. Tracking changes in B cell antibodies in cervical cancer patients treated with chemoradiation and immunotherapy on GOG 9929. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 124; 9/28/2025 Oral Presentation.

Kovalchuk N, Simiele E, LaRiviere M, Hiniker S, Han C, Dandapani S, Wong J, Soike M, Guo B, Cherian S, Shrestha D, Teruel J, Gerber N, Parsons D, Kumar K, Latifi K, Figura N, Xiao Y, Hoppe BS, Milgrom S. Implementing Advanced Total Body Irradiation (TBI) Techniques into Clinical Trials: An NRG Hematologic Malignancies Working Group Survey. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 3649; 9/29/2025 Poster Presentation.

Miccio JA, Hu C, Kong F, Samson PP, Gelblum DY, Loo BW Jr., Videtic GM, Faria SL, Jolly S, Tian S, Gerber D, Welsh JW, Nakhoul I, Gore EM, Lyness JA, Bradley JD, Machtay M. An Individual Patient Level Comparison Of Personalized Vs. Non-Personalized Radiation Dose Escalation In NSCLC. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 1048; 9/30/2025 Quick Pitch Oral Presentation.

Olson A, Wang H, Hall WA, Tran PT, Nguyen-Tan P, Michalski JM, Sandler HM, Roach M III, Rosenthal SA, Yee D, Winquist E, Shah A, Currey A, Kapadia NS, Duclos M, Lukka HR, Streeter OE, Efstathiou JA, Pugh SL, Nguyen PL. Hallmark interferon-alpha response analysis in localized prostate cancer: analysis of the NRG Oncology/RTOG 9202, 9413, 9902, 0126, and 0521 clinical trials. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 359; 10/1/2025 Oral Presentation.

Sim AJ, Hoppe BS, Ballas LK, Milgrom SA, Terezakis SA, Figura NB, Parikh RR, Grecula JC, Plastaras JP, Lo AC, Ryckman JM, Flampouri S, Pinnix CC, Kelsey CR. Consensus Organ at Risk Constraints for Radiation Therapy of Hematologic Malignancies for NCTN Trials. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 1101; 9/30/2025 Quick Pitch Oral Presentation.

Wang D, Yom SS, Henson CE, Dorth JA, Chan JW, Lominska CE, Harper JL, Gensheimer MF, Stokes WA, Robbins J, Mashru SH, Raben A, Kimple RJ, Bhateja P, Galloway TJ, Hitchcock YJ, Mani K, Wilke C, Le Q, Xiao Y. AI-Assisted Contour Quality Assurance For HN005 Clinical Trial. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 3735; 9/30/2025 Poster Presentation.

Wang L, Geng H, Sartor O, Chen Z, Ruo R, Yu J, Morgan S, Hoffman KE, Nguyen PL, Xiao Y. Feasibility Study of AI-Assisted Radiation Therapy Contour QA for Prostate Cancer Multi-Center Clinical Trial. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 356; 10/1/2025 Oral Presentation.

Yu J, Pugh SL, Ellis RJ, Feng FY, Frazier A, Pennington JD, Michalski JM, Spratt DE, Ghilezan M, Morgan SC, Mihai AM, Solanki AA, Amjad A, Straza MW, Menard C, Schroeder T, Marshall DT, Paulus R, Sandler HM. Quality of Life Results from NRG-GU005: A Phase III Trial of SBRT vs. Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 193; 9/29/2025 Quick Pitch Oral Presentation.

Yusuf M, Attwood K, Gross ND, Ashford B, Barker C, Chen Y, Nagarajan P, Rischin D, Schmitt N, Tam S, Wise-Draper TM, Ward MC, Wu XC, Yom SS. Radiation Planning in NRG-HN014, a Trial in Progress. Australia New Zealand Head Neck Cancer Society. 8/29/2025. Abstract # 43.

Zumsteg ZS, Luu M, Dignam JJ, Fortpied C, Jang JK, Chen MM, Mallen-St Clair J, Walgama E, Le Q, Machay M, Tribius S, Bernier J, Ozsahin EM, Lefebvre JL, Gregoire V, van Glabbeke M, Ho AS, Yom SS. Re-examining Post-operative Chemoradiotherapy in Head and Neck Cancer: An Updated Long-Term Combined Analysis of RTOG 9501/EORTC 22931. American Society for Radiation Oncology; Sep 27‒Oct 1, 2025. Abstract # 313; 9/30/2025 Oral Presentation.

PUBLISHED ARTICLES

Corrigan KL, Paulus R, Klopp AH, Wenzel LB, Yeung AR, Thompson JS, Doncals DE, Kundapur V, Wiggers NH, Mohan DS, Ghamande SA, Westin SN, Schnarr KL, Haas ML, Gaffney DK, Waggoner SE, Vanderwall PJ, Jastaniyah NT, Pugh SL, Kachnic LA. Patient-Reported Outcomes During Pelvic Radiation Therapy: A Secondary Analysis on Sexual Function From NRG-RTOG 1203. JCO Oncol Adv. 2025 May 12;2(1):e2400088. Doi: 10.1200/OA-24-00088. PMID: 40370492; PMCID: PMC12071503. Read more.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS:

American Brachytherapy Society (ABS); Jun 18-21, 2025; Nashville, TN

American Society of Clinical Oncology (ASCO); May 30-Jun 3, 2025; Chicago, IL

Canadian Association of Radiation Oncology (CARO); Sep 10-13, 2025; Calgary, AB

ESMO Gynaecological Cancers; Jun 19-21, 2025; Vienna, Austria

International Society for Quality-of-Life Research (ISOQOL); Oct 22-25, 2025; Milwaukee, WI

Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL

Western Association of Gynecologic Oncologists (WAGO); Jun 18-21, 2025; Colorado Springs, CO

UPCOMING ABSTRACT SUBMISSION DEADLINES:

AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Sep 18-21, 2025; Baltimore, MD; Due to publications committee Jun 10, 2025; Submission deadline Jun 24, 2025, 1:00 pm ET

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 22-26, 2025; Boston, MA; Due to publications committee Jul 7, 2025; Submission deadline Jul 21, 2025, 1:00 pm ET; LBA and Clinical Trials Sep 10, 2025, 1:00 pm ET

American Society for Radiation Oncology (ASTRO); Sep 28-Oct 1, 2025; San Francisco, CA; LBA Jul 10, 2025, 11:59 pm PT

European Society for Medical Oncology (ESMO); Oct 17-21, 2025; Berlin, Germany; Submission deadline May 13, 2025, 21:00 CET; LBA Sep 9, 2025, 21:00 CET (placeholder required)

ESMO Gastrointestinal Cancers; Jul 2-5, 2025; Barcelona, Spain; LBA Jun 5, 2025, 21:00 CET (placeholder required)

International Gynecologic Cancer Society (IGCS); Nov 5-7, 2025; Cape Town, South Africa; Submission deadline May 5, 2025, 23:59 SAST; LBA Sep 29, 2025 (placeholder required)

San Antonio Breast Cancer Symposium (SABCS); Dec 9-12, 2025; San Antonio, TX; Due to publications committee Jun 25, 2025; Submission deadline Jul 9, 2025, 6:00 pm CT; LBA Sep 30, 2025, 11:59 pm CT

Society for Immunotherapy of Cancer (SITC); Nov 5-9, 2025; National Harbor, MD; Due to publications committee Jun 12, 2025; Submission deadline Jun 26, 2025

Society for Neuro-Oncology (SNO); Nov 19-23, 2025; Honolulu, HI; Due to publications committee May 23, 2025; Submission deadline Jun 6, 2025, 11:59 pm ET; LBA Sep 2, 2025, 5:00 pm ET

Society of Urologic Oncology (SUO); Dec 2-5, 2025; Dallas, TX; Due to publications committee Jul 22, 2025; Submission deadline Aug 5, 2025